Morgan Stanley’s Core Laboratories CLB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.5M Sell
446,782
-38,256
-8% -$684K ﹤0.01% 3813
2025
Q4
$7.78M Sell
485,038
-19,156
-4% -$285K ﹤0.01% 3834
2025
Q3
$6.23M Buy
504,194
+22,649
+5% +$266K ﹤0.01% 3969
2025
Q2
$5.55M Sell
481,545
-108,034
-18% -$1.28M ﹤0.01% 3981
2025
Q1
$8.84M Sell
589,579
-305,193
-34% -$5.11M ﹤0.01% 3454
2024
Q4
$15.5M Sell
894,772
-113,282
-11% -$2.19M ﹤0.01% 3006
2024
Q3
$18.7M Sell
1,008,054
-67,048
-6% -$1.35M ﹤0.01% 2868
2024
Q2
$21.8M Buy
1,075,102
+31,421
+3% +$556K ﹤0.01% 2569
2024
Q1
$17.8M Sell
1,043,681
-411,351
-28% -$6.47M ﹤0.01% 2824
2023
Q4
$25.7M Buy
1,455,032
+767,748
+112% +$15.5M ﹤0.01% 3117
2023
Q3
$16.5M Buy
687,284
+160,139
+30% +$3.93M ﹤0.01% 2654
2023
Q2
$12.3M Buy
527,145
+96,718
+22% +$2.19M ﹤0.01% 2971
2023
Q1
$9.49M Buy
430,427
+27,587
+7% +$646K ﹤0.01% 3197
2022
Q4
$8.17M Buy
402,840
+43,154
+12% +$836K ﹤0.01% 3271
2022
Q3
$4.85M Buy
359,686
+2,116
+0.6% +$35.7K ﹤0.01% 3726
2022
Q2
$7.08M Buy
357,570
+72,872
+26% +$1.94M ﹤0.01% 3434
2022
Q1
$9.01M Sell
284,698
-21,167
-7% -$593K ﹤0.01% 3025
2021
Q4
$6.83M Sell
305,865
-16,871
-5% -$440K ﹤0.01% 3389
2021
Q3
$8.96M Sell
322,736
-297,982
-48% -$9.07M ﹤0.01% 3030
2021
Q2
$24.2M Buy
620,718
+472,415
+319% +$16.9M ﹤0.01% 1955
2021
Q1
$4.27M Sell
148,303
-2,310
-2% -$78.9K ﹤0.01% 3574
2020
Q4
$3.99M Buy
150,613
+16,498
+12% +$337K ﹤0.01% 3500
2020
Q3
$2.05M Buy
134,115
+3,885
+3% +$81.5K ﹤0.01% 3639
2020
Q2
$2.65M Sell
130,230
-746,196
-85% -$13.4M ﹤0.01% 3325
2020
Q1
$9.06M Buy
876,426
+507,141
+137% +$14.2M ﹤0.01% 1876
2019
Q4
$13.9M Buy
369,285
+89,116
+32% +$4M ﹤0.01% 2039
2019
Q3
$13.1M Buy
280,169
+68,262
+32% +$3.17M ﹤0.01% 1862
2019
Q2
$11.1M Buy
211,907
+25,130
+13% +$1.47M ﹤0.01% 2040
2019
Q1
$12.9M Buy
186,777
+75,395
+68% +$5.05M ﹤0.01% 1791
2018
Q4
$6.65M Sell
111,382
-63,371
-36% -$5.47M ﹤0.01% 2552
2018
Q3
$20.2M Sell
174,753
-14,211
-8% -$1.6M 0.01% 1671
2018
Q2
$23.8M Sell
188,964
-32,114
-15% -$3.91M 0.01% 1475
2018
Q1
$23.9M Sell
221,078
-17,879
-7% -$1.98M 0.01% 1507
2017
Q4
$26.2M Buy
238,957
+11,667
+5% +$1.16M 0.01% 1436
2017
Q3
$22.4M Buy
227,290
+75,567
+50% +$7.33M 0.01% 1476
2017
Q2
$15.4M Sell
151,723
-15,742
-9% -$1.7M ﹤0.01% 1759
2017
Q1
$19.3M Buy
167,465
+24,929
+17% +$2.9M 0.01% 1604
2016
Q4
$17.1M Sell
142,536
-45,063
-24% -$4.99M 0.01% 1680
2016
Q3
$21.1M Sell
187,599
-22,943
-11% -$2.64M 0.01% 1403
2016
Q2
$26.1M Sell
210,542
-217,488
-51% -$26.3M 0.01% 1221
2016
Q1
$48.1M Sell
428,030
-242,401
-36% -$25.2M 0.02% 773
2015
Q4
$72.9M Sell
670,431
-185,988
-22% -$21.3M 0.03% 614
2015
Q3
$85.5M Sell
856,419
-20,157
-2% -$2.19M 0.03% 531
2015
Q2
$100M Sell
876,576
-26,088
-3% -$3.16M 0.03% 511
2015
Q1
$94.3M Sell
902,664
-42,847
-5% -$4.56M 0.03% 524
2014
Q4
$114M Sell
945,511
-133,935
-12% -$17.6M 0.04% 461
2014
Q3
$158M Sell
1,079,446
-217,126
-17% -$33.5M 0.06% 350
2014
Q2
$217M Buy
1,296,572
+93,365
+8% +$16.6M 0.08% 265
2014
Q1
$239M Buy
1,203,207
+198,824
+20% +$37.5M 0.1% 235
2013
Q4
$192M Buy
1,004,383
+158,206
+19% +$29.4M 0.08% 277
2013
Q3
$143M Buy
846,177
+131,029
+18% +$20.3M 0.07% 333
2013
Q2
$108M Buy
+715,148
New +$101M 0.05% 379

Other funds holding CLB

Morgan Stanley's CLB Position: Q1 2026 in Review

Morgan Stanley reduced its Core Laboratories (CLB) stake by 7.9% in Q1 2026, selling an estimated $684K and leaving 446,782 shares worth $7.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3813.

Morgan Stanley first reported a position in CLB in Q2 2013 and has held it in 52 quarters since. The position peaked at $239M in Q1 2014. 190 funds tracked by Wall St. Rank hold CLB as of Q1 2026.

  • Morgan Stanley held 446,782 shares of Core Laboratories worth $7.5M as of Q1 2026.
  • Morgan Stanley sold 38,256 Core Laboratories shares in Q1 2026, an estimated $684K.
  • Core Laboratories made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #3813 holding.
  • Morgan Stanley first reported a position in Core Laboratories in Q2 2013 and has held it in 52 quarters since.
  • Morgan Stanley's Core Laboratories position peaked at $239M in Q1 2014.
  • 190 funds tracked by Wall St. Rank held Core Laboratories as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.